An unprecedented study reveals strategy to decrease the burden of alopecia areata, atopic dermatitis, psoriasis and other autoimmune conditions. A new study published in eLIFE by researchers from the ...

Cabaletta Bio, Inc. announced promising results from its ongoing RESET clinical trials for its investigational therapy rese-cel, focusing on autoimmune diseases. In the trials, notable outcomes ...

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient ...

Cabaletta Bio, Inc. announced promising clinical data regarding its investigational therapy, resecabtagene autoleucel (rese-cel), for autoimmune diseases during recent scientific meetings. Among the ...

Autoimmune diseases comprise more than 80 different diseases that have in common a burden on health systems and are of unknown etiology. In general, in most countries, autoimmune diseases affect an ...

Conduit Pharmaceuticals announced they will be conducting a Phase 2a clinical trial to evaluate AZD1656 for the treatment of multiple autoimmune diseases, including systemic lupus erythematosus (SLE), ...